These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10091628)

  • 1. Riluzole therapy in Huntington's disease (HD).
    Rosas HD; Koroshetz WJ; Jenkins BG; Chen YI; Hayden DL; Beal MF; Cudkowicz ME
    Mov Disord; 1999 Mar; 14(2):326-30. PubMed ID: 10091628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.
    Huntington Study Group
    Neurology; 2003 Dec; 61(11):1551-6. PubMed ID: 14663041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole in Huntington's disease (HD): an open label study with one year follow up.
    Seppi K; Mueller J; Bodner T; Brandauer E; Benke T; Weirich-Schwaiger H; Poewe W; Wenning GK
    J Neurol; 2001 Oct; 248(10):866-9. PubMed ID: 11697523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
    Jankovic J; Hunter C
    Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.
    Abdallah CG; Coplan JD; Jackowski A; Sato JR; Mao X; Shungu DC; Mathew SJ
    Neurosci Lett; 2012 Nov; 530(1):103-7. PubMed ID: 23043888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.
    Jenkins BG; Koroshetz WJ; Beal MF; Rosen BR
    Neurology; 1993 Dec; 43(12):2689-95. PubMed ID: 8255479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
    Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
    Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
    Bender A; Auer DP; Merl T; Reilmann R; Saemann P; Yassouridis A; Bender J; Weindl A; Dose M; Gasser T; Klopstock T
    J Neurol; 2005 Jan; 252(1):36-41. PubMed ID: 15672208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
    Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
    J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
    Armstrong MJ; Miyasaki JM;
    Neurology; 2012 Aug; 79(6):597-603. PubMed ID: 22815556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
    Grant P; Lougee L; Hirschtritt M; Swedo SE
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):761-7. PubMed ID: 18315448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label riluzole in fragile X syndrome.
    Erickson CA; Weng N; Weiler IJ; Greenough WT; Stigler KA; Wink LK; McDougle CJ
    Brain Res; 2011 Mar; 1380():264-70. PubMed ID: 21059347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of riluzole in Huntington's disease.
    Squitieri F; Ciammola A; Colonnese C; Ciarmiello A
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):221-2. PubMed ID: 17987289
    [No Abstract]   [Full Text] [Related]  

  • 16. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label trial of riluzole in generalized anxiety disorder.
    Mathew SJ; Amiel JM; Coplan JD; Fitterling HA; Sackeim HA; Gorman JM
    Am J Psychiatry; 2005 Dec; 162(12):2379-81. PubMed ID: 16330605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: present treatments and future therapeutic modalities.
    Bonelli RM; Wenning GK; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Mar; 19(2):51-62. PubMed ID: 15076012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.
    Saft C; Hoffmann R; Strassburger-Krogias K; Lücke T; Meves SH; Ellrichmann G; Krogias C
    J Neural Transm (Vienna); 2015 Jun; 122(6):825-33. PubMed ID: 25503829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.